Clinical trial Recruiting at 1 site Observational Ages 18 to 100

Super-resolution ultrasound imaging for peripheral artery disease

Official title: The Predictive Value of Super-resolution Ultrasound Microvascular Imaging for the Prognosis of Peripheral Artery Disease

Run by Peking University First Hospital · NCT07374601 · Data updated 2026-11-12

This project will test whether super-resolution contrast ultrasound can reveal small-vessel problems in adults with or without peripheral artery disease.

Quick facts

Study typeObservational
Ages18 Years to 100 Years
SexAll
Enrollment300 (estimated)
SponsorPeking University First Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedFebruary 8, 2026
Main results expectedDecember 31, 2027
Study endsDecember 31, 2028
Registry record updatedMay 18, 2026
Trial IDNCT07374601 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18–100 with confirmed peripheral artery disease or healthy adults without PAD who can consent and undergo contrast-enhanced ultrasound.

Probably not a fit

People who cannot undergo contrast-enhanced ultrasound (for example due to contrast allergy), who have severe involuntary movement disorders that prevent reliable imaging, or who cannot travel to the study site are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, single-center study uses super-resolution contrast-enhanced ultrasound to image the muscle and skin microvasculature in adults with clinically confirmed peripheral artery disease and in healthy control volunteers. Participants undergo ankle-brachial index screening and vascular imaging to confirm group assignment, then receive contrast-enhanced ultrasound with microbubble tracking to visualize arterioles and capillaries ≤100 micrometers. Investigators will compare microvascular structure and perfusion measures between PAD patients and controls to characterize microvascular dysfunction. The study is conducted at Peking University First Hospital in Beijing and does not alter participants' medical treatments.

Why it matters

Potential benefit: If successful, this imaging approach could help detect microvascular dysfunction earlier and guide more personalized care for people with peripheral artery disease.

How similar studies have gone: Early research and pilot studies of super-resolution and contrast-enhanced ultrasound have shown promise for visualizing microvascular networks, but applying SRUMI specifically to PAD is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
\*Inclusion Criteria:\*

1. Adults aged ≥18 years and ≤100 years;
2. Diagnosis of peripheral artery disease (PAD) confirmed by comprehensive clinical assessment-including characteristic symptoms (e.g., intermittent claudication, rest pain), physical findings (e.g., diminished or absent distal pulses, bruits), ankle-brachial index (ABI) \< 0.9, and corroborating vascular imaging (e.g., duplex ultrasonography, CTA, or MRA);
3. Alternatively, healthy adults without PAD (i.e., ABI ≥ 0.9, absence of suggestive symptoms or signs, and no history of atherosclerotic cardiovascular disease) who meet all other eligibility requirements;
4. Willing and able to provide written informed consent.

\*Exclusion Criteria:\*

1. Inability to complete study procedures due to:

   1. Severe involuntary movement disorders (e.g., advanced Parkinson's disease or cerebellar ataxia) interfering with image acquisition;
   2. Contraindication to contrast-enhanced ultrasound (e.g., documented hypersensitivity to sulfur hexafluoride microbubble contrast agent \[SonoVue®\]);
   3. Active lower-limb infection (e.g., diabetic foot infection with systemic signs or osteomyelitis), which precludes safe or interpretable data collection;
2. Cognitive impairment or legal incapacity precluding autonomous informed consent;
3. Refusal-by the participant or their legally authorized representative-to provide informed consent.

Where it's running

  • Peking University First Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.